Immune Resistance Mechanisms and the Road to Personalized Immunotherapy.

What does the future of cancer immunotherapy look like and how do we get there? Find out where we've been and where we're headed in A Report on Resistance: The Road to personalized immunotherapy.

[1]  Jinlin Huang,et al.  Estimation of cell lineages in tumors from spatial transcriptomics data , 2023, Nature Communications.

[2]  R. Aharonov,et al.  Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome , 2022, bioRxiv.

[3]  M. Blaser,et al.  Tumor microbiome links cellular programs and immunity in pancreatic cancer. , 2022, Cancer cell.

[4]  E. Ruppin,et al.  Big data in basic and translational cancer research , 2022, Nature Reviews Cancer.

[5]  T. Burns,et al.  OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC , 2022, Journal of Thoracic Oncology.

[6]  S. Hu-Lieskovan,et al.  The role of biomarkers in personalized immunotherapy , 2022, Biomarker research.

[7]  Dominik,et al.  High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer , 2022, bioRxiv.

[8]  Y. Chae,et al.  Role of mass spectrometry-based serum proteomics signatures in predicting clinical outcomes and toxicity in patients with cancer treated with immunotherapy , 2022, Journal for ImmunoTherapy of Cancer.

[9]  Eun Sug Park,et al.  Spatial CRISPR genomics identifies regulators of the tumor microenvironment , 2022, Cell.

[10]  J. Gartner,et al.  Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers , 2022, Science.

[11]  S. Raychaudhuri,et al.  TCR-sequencing in cancer and autoimmunity: barcodes and beyond. , 2022, Trends in immunology.

[12]  Parisa Sharifi,et al.  Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. , 2021, Clinical immunology.

[13]  Hameed M. Jasim,et al.  FOXP3 and IL-10 overexpression: A novel diagnostic biomarker in Iraqi patients having Hyperthyroidism treated with radioactive iodine , 2021, Gene Reports.

[14]  S. Ugel,et al.  A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment , 2021, Cells.

[15]  E. Ruppin,et al.  Systematic Investigation of Cytokine Signaling Activity at the Tissue and Single-Cell Level , 2021, Nature Methods.

[16]  S. Dan,et al.  Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal , 2021, Journal for ImmunoTherapy of Cancer.

[17]  Jia Wei,et al.  Beta2-microglobulin(B2M) in cancer immunotherapies: Biological function, resistance and remedy. , 2021, Cancer letters.

[18]  D. Mitchell,et al.  Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy , 2021, Frontiers in Oncology.

[19]  A. Fernández-Medarde,et al.  40 Years of RAS—A Historic Overview , 2021, Genes.

[20]  Yu Qin,et al.  Neoantigen: A New Breakthrough in Tumor Immunotherapy , 2021, Frontiers in Immunology.

[21]  A. Griffioen,et al.  Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes , 2021, Nature Reviews Clinical Oncology.

[22]  E. Ruppin,et al.  Synthetic lethality-mediated precision oncology via the tumor transcriptome , 2021, Cell.

[23]  Hunter M Nisonoff,et al.  XYZeq: Spatially resolved single-cell RNA sequencing reveals expression heterogeneity in the tumor microenvironment , 2021, Science Advances.

[24]  James E. Clune,et al.  Circulating clonally expanded T cells reflect functions of tumor-infiltrating T cells , 2021, The Journal of experimental medicine.

[25]  K. McCoy,et al.  Impact of the microbiome on tumor immunity. , 2021, Current opinion in immunology.

[26]  Qi-xue Wang,et al.  Putting Proteomics Into Immunotherapy for Glioblastoma , 2021, Frontiers in Immunology.

[27]  P. Ott,et al.  Advances in the development of personalized neoantigen-based therapeutic cancer vaccines , 2021, Nature Reviews Clinical Oncology.

[28]  Wei Huang,et al.  Targeting STAT3 in Cancer Immunotherapy , 2020, Molecular cancer.

[29]  P. Romero,et al.  Metabolic and epigenetic regulation of T-cell exhaustion , 2020, Nature Metabolism.

[30]  M. Azuma,et al.  Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells , 2020, Inflammation.

[31]  Trevor J Pugh,et al.  Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab , 2020, Nature Cancer.

[32]  E. Ruppin,et al.  Predicting cancer prognosis and drug response from the tumor microbiome , 2020, Nature Communications.

[33]  Shuhua Wei,et al.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects , 2020, Molecular Cancer.

[34]  M. Tolba.  Revolutionizing the landscape of colorectal cancer treatment: The potential role of immune checkpoint inhibitors , 2020, International journal of cancer.

[35]  P. Harari,et al.  The Promise of Combining Radiation Therapy with Immunotherapy. , 2020, International journal of radiation oncology, biology, physics.

[36]  Jeffrey J. Quinn,et al.  Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts , 2020, Science.

[37]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[38]  T. Jiang,et al.  Heterogeneity of neoantigen landscape between primary lesions and their matched metastases in lung cancer , 2020, Translational lung cancer research.

[39]  Rob Knight,et al.  Microbiome analyses of blood and tissues suggest cancer diagnostic approach , 2020, Nature.

[40]  K. Shaw,et al.  Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies , 2020, Oncotarget.

[41]  P. V. van Dam,et al.  The potential and controversy of targeting STAT family members in cancer. , 2020, Seminars in cancer biology.

[42]  A. Schäffer,et al.  The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective , 2020, Nature Communications.

[43]  Hui Luo,et al.  Microsatellite instability: a review of what the oncologist should know , 2020, Cancer Cell International.

[44]  T. Dzieciątkowski,et al.  The Intriguing History of Cancer Immunotherapy , 2019, Front. Immunol..

[45]  B. Parker,et al.  JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression , 2019, Cancers.

[46]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[47]  E. Sokol,et al.  Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. , 2019, The oncologist.

[48]  G. Tortora,et al.  Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story , 2019, Cancers.

[49]  Yulun Huang,et al.  Histone deacetylase inhibition up-regulates MHC class I to facilitate cytotoxic T lymphocyte-mediated tumor cell killing in glioma cells , 2019, Journal of Cancer.

[50]  Martin L. Miller,et al.  UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma , 2019, Cell.

[51]  Siwei Wang,et al.  Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy , 2019, Journal of Hematology & Oncology.

[52]  I. Melero,et al.  Twists and turns to translating 4-1BB cancer immunotherapy , 2019, Science Translational Medicine.

[53]  P. Bankhead,et al.  Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells , 2019, Front. Immunol..

[54]  C. Figdor,et al.  Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity , 2019, Front. Immunol..

[55]  D. Burgess.  Spatial transcriptomics coming of age , 2019, Nature Reviews Genetics.

[56]  D. Vignali,et al.  Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. , 2019, Seminars in immunology.

[57]  J. Varner,et al.  Targeting Tumor-Associated Macrophages in Cancer. , 2019, Trends in immunology.

[58]  A. Sabò,et al.  MYC in Germinal Center‐derived lymphomas: Mechanisms and therapeutic opportunities , 2019, Immunological reviews.

[59]  Evan Z. Macosko,et al.  Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution , 2019, Science.

[60]  S. Karam,et al.  Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment , 2019, Front. Immunol..

[61]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[62]  P. van Endert,et al.  microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients. , 2018, Gastroenterology.

[63]  Ludovic C. Gillet,et al.  Data‐independent acquisition‐based SWATH‐MS for quantitative proteomics: a tutorial , 2018, Molecular systems biology.

[64]  E. Jaffee,et al.  T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma. , 2018, JCI insight.

[65]  Li Tang,et al.  Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy , 2018, Front. Immunol..

[66]  R. Niu,et al.  JAK2 and PD‐L1 Amplification Enhance the Dynamic Expression of PD‐L1 in Triple‐negative Breast Cancer , 2018, Clinical breast cancer.

[67]  Xue Zhang,et al.  The promising immune checkpoint LAG-3: from tumor microenvironment to cancer immunotherapy , 2018, Genes & cancer.

[68]  J. Utikal,et al.  Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression , 2018, Front. Immunol..

[69]  L. Macconaill,et al.  Frameshift events predict anti-PD-1/L1 response in head and neck cancer. , 2018, JCI insight.

[70]  M. Berger,et al.  Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy , 2018, Science.

[71]  P. Agostinis,et al.  Defining the role of the tumor vasculature in antitumor immunity and immunotherapy , 2018, Cell Death & Disease.

[72]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[73]  C. Zahnow,et al.  DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer , 2018, Nature Communications.

[74]  G. Evan,et al.  Myc Cooperates with Ras by Programming Inflammation and Immune Suppression , 2017, Cell.

[75]  Z. Trajanoski,et al.  Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy , 2017, Front. Immunol..

[76]  J. Rathmell,et al.  Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors. , 2017, Cell metabolism.

[77]  A. Kulkarni,et al.  STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC , 2017, Journal of dental research.

[78]  Daniela Massi,et al.  PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. , 2017, Seminars in cancer biology.

[79]  D. Grandér,et al.  PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma , 2017, Leukemia.

[80]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[81]  Yi Zhang,et al.  Tumor-associated macrophages: from basic research to clinical application , 2017, Journal of Hematology & Oncology.

[82]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[83]  H. Ishwaran,et al.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade , 2016, Cell.

[84]  J. Kutok,et al.  Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells , 2016, Nature.

[85]  Jayoung Kim,et al.  Trends in Next-Generation Sequencing and a New Era for Whole Genome Sequencing , 2016, International neurourology journal.

[86]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[87]  N. Zhang,et al.  The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. , 2016, International journal of oncology.

[88]  F. M. Marincola,et al.  Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 , 2016, Journal of Translational Medicine.

[89]  Philippe Foubert,et al.  PI3Kγ is a molecular switch that controls immune suppression , 2016, Nature.

[90]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[91]  J. Larkin,et al.  Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. , 2016, Journal of the National Cancer Institute.

[92]  Mari Mino-Kenudson,et al.  PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes , 2016, Modern Pathology.

[93]  G. Nolan,et al.  Mass Cytometry: Single Cells, Many Features , 2016, Cell.

[94]  A. Bergenheim,et al.  Characterization of the serum metabolome following radiation treatment in patients with high-grade gliomas , 2016, Radiation Oncology.

[95]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[96]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[97]  Xifeng Wu,et al.  Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes , 2016, Oncotarget.

[98]  I. Sheyhidin,et al.  Metabonomic signature analysis in plasma samples of glioma patients based on (1)H-nuclear magnetic resonance spectroscopy. , 2016, Neurology India.

[99]  M. Fassan,et al.  Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer , 2016, Cell Death and Disease.

[100]  M. Cvancarova,et al.  Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination , 2015, Cancer Immunology, Immunotherapy.

[101]  Shasha Wei,et al.  Quantitative proteomics using SILAC: Principles, applications, and developments , 2015, Proteomics.

[102]  J. Madore,et al.  PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials , 2015, Pigment cell & melanoma research.

[103]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[104]  D. Fearon,et al.  T cell exclusion, immune privilege, and the tumor microenvironment , 2015, Science.

[105]  T. Graeber,et al.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.

[106]  Alexander van Oudenaarden,et al.  Spatially resolved transcriptomics and beyond , 2014, Nature Reviews Genetics.

[107]  Y. Kluger,et al.  PTEN functions as a melanoma tumor suppressor by promoting host immune response , 2014, Oncogene.

[108]  E. Petricoin,et al.  A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[109]  L. Radvanyi,et al.  The IL-2 cytokine family in cancer immunotherapy. , 2014, Cytokine & growth factor reviews.

[110]  Brendan MacLean,et al.  CPTAC Assay Portal: a repository of targeted proteomic assays , 2014, Nature Methods.

[111]  S. Rosenberg.  IL-2: The First Effective Immunotherapy for Human Cancer , 2014, The Journal of Immunology.

[112]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[113]  Dean Sheppard,et al.  TGF-β activation and function in immunity. , 2014, Annual review of immunology.

[114]  C. Rommel,et al.  PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.

[115]  J. Geschwind,et al.  Tumor glycolysis as a target for cancer therapy: progress and prospects , 2013, Molecular Cancer.

[116]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[117]  S. Jeffrey,et al.  Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? , 2013, Genome Medicine.

[118]  Hao Liu,et al.  Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[119]  Jun Hu,et al.  PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer , 2013, PloS one.

[120]  T. Malek,et al.  IL-2R Signaling Is Essential for Functional Maturation of Regulatory T Cells during Thymic Development , 2013, The Journal of Immunology.

[121]  R. Boldrini,et al.  IRF1 and NF-kB Restore MHC Class I-Restricted Tumor Antigen Processing and Presentation to Cytotoxic T Cells in Aggressive Neuroblastoma , 2012, PloS one.

[122]  F. Marincola,et al.  The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.

[123]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[124]  D. Hafler,et al.  The TIGIT/CD226 Axis Regulates Human T Cell Function , 2012, The Journal of Immunology.

[125]  Phillip C. Wright,et al.  An insight into iTRAQ: where do we stand now? , 2012, Analytical and Bioanalytical Chemistry.

[126]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[127]  E John Wherry,et al.  T cell exhaustion , 2011 .

[128]  J. Rathmell,et al.  Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets , 2011, The Journal of Immunology.

[129]  Vijay K. Kuchroo,et al.  Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions , 2011, The Journal of Immunology.

[130]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[131]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[132]  E. Thorsby,et al.  A short history of HLA. , 2009, Tissue antigens.

[133]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[134]  G. Freeman,et al.  IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection , 2008, Proceedings of the National Academy of Sciences.

[135]  Olivier De Wever,et al.  Stromal myofibroblasts are drivers of invasive cancer growth , 2008, International journal of cancer.

[136]  T. Gajewski,et al.  Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells , 2008, European journal of immunology.

[137]  P. Dahm,et al.  Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. , 2008, Journal of immunology.

[138]  S. Ishihara,et al.  CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation–mediated apoptosis of effector CD4+ T cells , 2007, Nature Immunology.

[139]  A. Rudensky,et al.  Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3− precursor cells in the absence of interleukin 10 , 2007, Nature Immunology.

[140]  T. Nomura,et al.  Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1 , 2007, Nature.

[141]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[142]  D. Galson,et al.  Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.

[143]  J. Stroud,et al.  FOXP3 Controls Regulatory T Cell Function through Cooperation with NFAT , 2006, Cell.

[144]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[145]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[146]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[147]  Andrew H. Thompson,et al.  Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. , 2003, Analytical chemistry.

[148]  C. Akdis,et al.  Mechanisms of interleukin‐10‐mediated immune suppression , 2001, Immunology.

[149]  M. Boyano,et al.  Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and interleukin-10 serum levels in patients withelanoma , 2000, British Journal of Cancer.

[150]  G. Bismuth,et al.  CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. , 1998, Journal of immunology.

[151]  J. D. de Vries,et al.  Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. , 1998, Journal of immunology.

[152]  N. Davidson,et al.  Studies with IL‐10‐/‐ mice: an overview , 1997, Journal of leukocyte biology.

[153]  J. D. Watson.  The human genome project: past, present, and future. , 1990, Science.

[154]  Michael P. Lisanti,et al.  Cancer metabolism: a therapeutic perspective , 2017, Nature Reviews Clinical Oncology.

[155]  P. Gimotty,et al.  Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy , 2008, Nature Medicine.

[156]  R. Coffman,et al.  Interleukin-10 and the interleukin-10 receptor. , 2001, Annual review of immunology.

[157]  M Aguet,et al.  The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.